Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Cell Biochem. 2014 Oct;115(10):1799-807. doi: 10.1002/jcb.24850.

Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells.

Author information

  • 1Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35255.

Abstract

Emerging evidence indicates that activation of Wnt/β-catenin signaling at the cell surface results in inhibition of glycogen synthase kinase 3β (GSK3β), leading to activation of mTORC1 signaling in cancer cells. The low density lipoprotein receptor-related protein-6 (LRP6) is an essential Wnt co-receptor for Wnt/β-catenin signaling. Salinomycin is a novel small molecule inhibitor of LRP6. In the present study, we found that LRP6 overexpression induced mTORC1 signaling activation in cancer cells, and that salinomycin was not only a potent Wnt/β-catenin signaling inhibitor, but also a strong mTORC1 signaling antagonist in breast and prostate cancer cells. Mechanistically, salinomycin activated GSK3β in cancer cells. Moreover, salinomycin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/β-catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity. Our results present novel mechanisms underlying salinomycin-mediated cancer cell death.

© 2014 Wiley Periodicals, Inc.

KEYWORDS:

CANCER; LRP6; SALINOMYCIN; Wnt SIGNALING; mTORC1 SIGNALING

PMID:
24905570
[PubMed - in process]
PMCID:
PMC4134741
[Available on 2015/10/1]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk